高流量鼻导管氧疗用于COVID-19严重低氧血症:氧合反应与结局
该研究基于已发表数据,分析接受HFNO或NIV且PaO2/FiO2≤300的COVID-19患者,比较HFNO期间与插管后ARDS标准的符合比例及28天死亡率。结果显示HFNO组持续治疗者28天死亡率4.2%,转为IMV者28.6%(P<0.001);NIV组分别为1.6%和44.9%(P<0.001)。结论提示将HFNO患者纳入ARDS定义可能识别早期但死亡率较低的患者。
要点
- HFNO治疗中PaO2/FiO2≤300的患者转为IMV后多数仍符合ARDS标准
- HFNO持续治疗者28天死亡率4.2%,转为IMV者28.6%
- NIV持续治疗者28天死亡率1.6%,转为IMV者44.9%
核心结论
- 将接受HFNO且PaO2/FiO2≤300的患者纳入ARDS定义,可能识别出疾病较早阶段但死亡率较低的患者。
研究设计与样本
- 基于已发表研究的分析,纳入COVID-19患者,HFNO组184例,NIV组131例,比较HFNO/NIV期间与插管后ARDS标准符合情况及28天死亡率。
主要发现
- HFNO组112例转为IMV,其中104例(92.9%)插管后仍PaO2/FiO2≤300;NIV组69例转为IMV,其中66例(95.7%)仍≤300。
- HFNO持续治疗者28天死亡率4.2%(3/72),转为IMV者28.6%(32/112),P<0.001。
- NIV持续治疗者28天死亡率1.6%(1/62),转为IMV者44.9%(31/69),P<0.001。
- 总体死亡率HFNO组19.0%(35/184),NIV组24.4%(32/131),P=0.2479。
关键数值与推荐
- HFNO纳入条件:PaO2/FiO2≤300且接受≥40 L/min HFNO;NIV对照条件:PEEP≥5 cm H2O。
- ARDS标准在HFNO期间及插管后早期评估,以PaO2/FiO2≤300为界。
临床怎么用
- 对HFNO治疗中PaO2/FiO2≤300的COVID-19患者,应警惕病情可能进展至需IMV,并密切监测。
- HFNO期间符合低氧血症标准但未插管者死亡率较低,提示拓宽ARDS定义可能有助于早期识别。
局限性
- 研究基于既往已发表数据的分析,非前瞻性设计。
- 仅纳入COVID-19患者,结论外推至其他病因ARDS需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rationale: The "Berlin definition" of acute respiratory distress syndrome (ARDS) does not allow inclusion of patients receiving high-flow nasal oxygen (HFNO). However, several articles have proposed that criteria for defining ARDS should be broadened to allow inclusion of patients receiving HFNO. Objectives: To compare the proportion of patients fulfilling ARDS criteria during HFNO and soon after intubation, and 28-day mortality between patients treated exclusively with HFNO and patients transitioned from HFNO to invasive mechanical ventilation (IMV). Methods: From previously published studies, we analyzed patients with coronavirus disease (COVID-19) who had PaO2/FiO2 of ⩽300 while treated with ⩾40 L/min HFNO, or noninvasive ventilation (NIV) with positive end-expiratory pressure of ⩾5 cm H2O (comparator). In patients transitioned from HFNO/NIV to invasive mechanical ventilation (IMV), we compared ARDS severity during HFNO/NIV and soon after IMV. We compared 28-day mortality in patients treated exclusively with HFNO/NIV versus patients transitioned to IMV. Measurements and Main Results: We analyzed 184 and 131 patients receiving HFNO or NIV, respectively. A total of 112 HFNO and 69 NIV patients transitioned to IMV. Of those, 104 (92.9%) patients on HFNO and 66 (95.7%) on NIV continued to have PaO2/FiO2 ⩽300 under IMV. Twenty-eight-day mortality in patients who remained on HFNO was 4.2% (3/72), whereas in patients transitioned from HFNO to IMV, it was 28.6% (32/112) (P < 0.001). Twenty-eight-day mortality in patients who remained on NIV was 1.6% (1/62), whereas in patients who transitioned from NIV to IMV, it was 44.9% (31/69) (P < 0.001). Overall mortality was 19.0% (35/184) and 24.4% (32/131) for HFNO and NIV, respectively (P = 0.2479). Conclusions: Broadening the ARDS definition to include patients on HFNO with PaO2/FiO2 ⩽300 may identify patients at earlier stages of disease but with lower mortality.
引用
- Ranieri VM, Tonetti T, Navalesi P, et al. High-Flow Nasal Oxygen for Severe Hypoxemia: Oxygenation Response and Outcome in Patients with COVID-19. Am J Respir Crit Care Med. 2022. PMID: 34861135. doi:10.1164/rccm.202109-2163OC
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。